MiNK Therapeutics (NASDAQ:INKT) Announces Earnings Results, Beats Estimates By $0.14 EPS

MiNK Therapeutics (NASDAQ:INKT) announced its quarterly earnings data on Tuesday. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.14, FiscalAI reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK highlighted durable clinical signals in oncology, including median overall survival >23 months and complete remissions beyond two years in heavily pretreated solid tumors, supported by coordinated immune activation without systemic toxicity.
• Early ARDS/hypoxemic pneumonia results showed tolerability at 1 billion cells, apparent reduction in harmful inflammation, pathogen clearance and much higher survival in treated patients (70% vs ~10% historical controls), and MiNK is initiating a randomized phase II trial with initial data expected in H2 2026.
• The company emphasized capital efficiency and non-dilutive funding—NIH/NIAID, Mary Goos, C‑Further and other sources—while reporting cash of $13.4M at year-end plus $3M raised post-year-end, which management says extends runway into 2026.
• Despite cost reductions, MiNK reported a full‑year net loss of $12.5M and a cash runway that currently extends only through 2026, meaning additional financing may be required to support multi‑program development and larger randomized trials.
• Management said no formal collaborations have been announced for combination trials (e.g., IL‑15 agonists) despite some trials appearing publicly, noting ongoing discussions—investors should treat combination reports as unconfirmed until official announcements.

MiNK Therapeutics Trading Up 0.4%

Shares of MiNK Therapeutics stock opened at $10.57 on Thursday. The firm has a market cap of $49.57 million, a P/E ratio of -3.56 and a beta of 0.35. MiNK Therapeutics has a 12 month low of $6.34 and a 12 month high of $76.00. The stock’s fifty day moving average price is $10.92 and its 200-day moving average price is $12.23.

Analysts Set New Price Targets

Several analysts have recently weighed in on INKT shares. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of MiNK Therapeutics in a research report on Wednesday. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $35.00.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.